CL2014000270A1 - Compuestos derivados de 3,5-difenil diazoles sustituidos, inhibidores de la agregacion de proteinas. (divisional de la solicitud n° 1369-2010). - Google Patents

Compuestos derivados de 3,5-difenil diazoles sustituidos, inhibidores de la agregacion de proteinas. (divisional de la solicitud n° 1369-2010).

Info

Publication number: CL2014000270A1
Authority: CL; Chile
Prior art keywords: diazoles; divisional; diphenyl; inhibitors; substituted
Prior art date: 2008-06-09

Application number

CL2014000270A

Other languages

English (en)

Inventor

Armin Giese

Uwe Bertsch

Hans Kretzschmar

Thomas Hirschberger

Paul Tavan

Christian Griesinger

Andrei Leonov

Sergey Ryazanov

Petra Weber

Markus Geissen

Martin H Groschup

Jens Wagner

Matthias Habeck

Original Assignee

Ludwing Maximilians Uni Munchen

Max Planck Gesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-09

Filing date

2014-02-03

Publication date

2014-10-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40942347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-02-03 Application filed by Ludwing Maximilians Uni Munchen, Max Planck Gesellschaft filed Critical Ludwing Maximilians Uni Munchen

2014-10-17 Publication of CL2014000270A1 publication Critical patent/CL2014000270A1/es

Links

JXHKUYQCEJILEI-UHFFFAOYSA-N 3,5-diphenyl-1h-pyrazole Chemical class C=1C(C=2C=CC=CC=2)=NNC=1C1=CC=CC=C1 JXHKUYQCEJILEI-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003112 inhibitor Chemical class 0.000 title 1
230000004845 protein aggregation Effects 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biochemistry (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)

CL2014000270A 2008-06-09 2014-02-03 Compuestos derivados de 3,5-difenil diazoles sustituidos, inhibidores de la agregacion de proteinas. (divisional de la solicitud n° 1369-2010). CL2014000270A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP08010458		2008-06-09

Publications (1)

Publication Number	Publication Date
CL2014000270A1 true CL2014000270A1 (es)	2014-10-17

Family

ID=40942347

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2010001369A CL2010001369A1 (es)	2008-06-09	2010-12-07	Compuestos derivados de 3,5-difenilpirazol, 3,5-difenilisoxazol, 2,4-difenilimidazol, 1,4-difenilpirrol, 3,5-difenil-1,2,4-oxadiazol; composicion farmaceutica; kit farmaceutico; utiles para tratar o prevenir una enfermedad relacionada con la agregacion de proteinas y/o neurodegenerativa, tales como enfermedad de prion, parkinson, alzheimer, entre otras.
CL2014000270A CL2014000270A1 (es)	2008-06-09	2014-02-03	Compuestos derivados de 3,5-difenil diazoles sustituidos, inhibidores de la agregacion de proteinas. (divisional de la solicitud n° 1369-2010).

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL2010001369A CL2010001369A1 (es)	2008-06-09	2010-12-07	Compuestos derivados de 3,5-difenilpirazol, 3,5-difenilisoxazol, 2,4-difenilimidazol, 1,4-difenilpirrol, 3,5-difenil-1,2,4-oxadiazol; composicion farmaceutica; kit farmaceutico; utiles para tratar o prevenir una enfermedad relacionada con la agregacion de proteinas y/o neurodegenerativa, tales como enfermedad de prion, parkinson, alzheimer, entre otras.

Country Status (21)

Country	Link
US (3)	US20110293520A1 (es)
EP (3)	EP2307381B1 (es)
JP (3)	JP5896739B2 (es)
KR (1)	KR101787112B1 (es)
CN (1)	CN102056903B (es)
AU (1)	AU2009266098B2 (es)
BR (2)	BRPI0913609B8 (es)
CA (1)	CA2726999C (es)
CL (2)	CL2010001369A1 (es)
DK (2)	DK2307381T3 (es)
ES (2)	ES2862923T3 (es)
HU (2)	HUE043090T2 (es)
IL (1)	IL208377A (es)
MX (1)	MX339144B (es)
NZ (1)	NZ588442A (es)
PL (2)	PL2684873T3 (es)
PT (2)	PT2684873T (es)
RU (1)	RU2531915C2 (es)
TR (1)	TR201904041T4 (es)
WO (1)	WO2010000372A2 (es)
ZA (1)	ZA201008820B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8829198B2 (en)	2007-10-31	2014-09-09	Proteotech Inc	Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US8916598B2 (en)	2003-05-30	2014-12-23	Proteotech Inc	Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
WO2009111611A2 (en)	2008-03-05	2009-09-11	Proteotech Inc.	Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
JP5361316B2 (ja) *	2008-10-02	2013-12-04	株式会社タムラ製作所	表面処理剤、プリント回路基板およびその製造方法
HRP20170737T1 (hr) *	2010-04-29	2017-07-28	Ionis Pharmaceuticals, Inc.	Modulacija ekspresije transtiretina
US8865754B2 (en)	2011-03-03	2014-10-21	Proteotech Inc.	Compounds for the treatment of neurodegenerative diseases
GB201113538D0 (en)	2011-08-04	2011-09-21	Karobio Ab	Novel estrogen receptor ligands
GB201116017D0 (en) *	2011-09-16	2011-10-26	Univ Surrey	Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
CN104693121B (zh) *	2014-11-14	2017-10-20	广州市爱菩新医药科技有限公司	一类具有抗老年痴呆活性的吡唑类化合物、制备方法与应用
CN108473516B (zh) *	2015-12-14	2021-06-18	马克斯·普朗克科学促进协会	3,5-二苯基-二唑化合物的水溶性衍生物
US10709688B2 (en)	2016-03-31	2020-07-14	Tohoku University	Agent for treating synucleinopathy
GB201611840D0 (en)	2016-07-07	2016-08-24	Univ Court Of The Univ Of Edinburgh The	Alpha-synuclein detection assay
KR101956302B1 (ko) *	2016-11-30	2019-03-11	연세대학교 산학협력단	세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물
EA201991720A1 (ru)	2017-02-17	2020-01-20	Бристол-Маерс Сквибб Компани	Антитела к альфа-синуклеину и их применения
JP7283699B2 (ja) *	2017-05-12	2023-05-30	マックス－プランク－ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ	黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
EP3886854A4 (en)	2018-11-30	2022-07-06	Nuvation Bio Inc.	Pyrrole and pyrazole compounds and methods of use thereof
CN109726510B (zh) *	2019-01-23	2022-12-23	山东大学	一种蛋白质糖化位点鉴定方法
US20230067910A1 (en)	2019-11-19	2023-03-02	Modag Gmbh	Novel compounds for the diagnosis, treatment and prevention of diseases associated with the aggregation of alpha-synuclein
CN111138376A (zh) *	2019-12-24	2020-05-12	中山大学	一种3,5-二取代苯基-1,2,4-噁二唑衍生物及其制备方法和应用
CN111848516B (zh) *	2020-08-04	2022-04-01	山东大学	溴酚-吡唑啉类化合物及其合成方法和应用
KR102746418B1 (ko) *	2020-12-03	2024-12-26	동국대학교 산학협력단	N-아세틸-l-아르기닌을 포함하는 단백질 응집 억제용 조성물
CN113045507B (zh) *	2021-03-04	2022-10-25	中山大学南方学院	一种3,4-二羟基苯甲酸甲酯衍生物及其制备方法与应用
CN113552102B (zh) *	2021-07-16	2022-05-17	上海交通大学	一种基于荧光相关光谱检测有机溶剂诱导蛋白聚集的药物筛选方法
CA3231484A1 (en)	2021-10-01	2023-04-06	Qinwen Mao	Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
EP4173485A1 (en)	2021-10-27	2023-05-03	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Protein aggregation inhibiting compounds for plant disease control
CN114573570B (zh) *	2022-02-21	2023-05-30	中山大学	一类α-突触核蛋白靶向化合物及其制备方法和应用
IL314952A (en) *	2022-03-01	2024-10-01	Modag Gmbh	Pharmaceutical preparation containing diphenyldiazole history and methods of use
CN115337301A (zh) *	2022-07-22	2022-11-15	汕头大学医学院第一附属医院	Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用
TW202412787A (zh)	2022-07-29	2024-04-01	日商住友製藥股份有限公司	2(1h)-吡啶亞胺衍生物
TW202415651A (zh)	2022-07-29	2024-04-16	日商住友製藥股份有限公司	含氮飽和雜環衍生物
CN115650957B (zh) *	2022-09-16	2023-12-15	中山大学	一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用
EP4602041A1 (en) *	2022-10-14	2025-08-20	Arcus Biosciences, Inc.	Hpk1 inhibitors and methods of use thereof
CN117045647A (zh) *	2023-08-03	2023-11-14	浙江大学	4-羟基吡唑类化合物及其衍生物和盐在制备抑制铁死亡药物中的应用
KR102904857B1 (ko) *	2023-09-04	2025-12-26	가천대학교 산학협력단	혈액 tdp-43 올리고머 측정을 통한 tdp-43 관련 질병 진단법
IL327370A (en)	2023-09-26	2026-05-01	Teva Pharmaceutical Ind Ltd	Methods and systems for detecting movement disorder progression
US11912675B1 (en)	2023-10-11	2024-02-27	King Faisal University	N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound
US11897850B1 (en)	2023-10-11	2024-02-13	King Faisal University	N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound
US11919872B1 (en)	2023-10-11	2024-03-05	King Faisal University	N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
US11891366B1 (en)	2023-10-12	2024-02-06	King Faisal University	4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
WO2026084453A1 (ko) *	2024-10-15	2026-04-23	재단법인대구경북과학기술원	혈액-뇌 장벽 투과용 약물전달체 및 이를 포함하는 뇌 질환 치료 또는 진단용 조성물

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL242505A (es) *	1958-08-20
CH426848A (de) *	1960-03-01	1966-12-31	Ciba Geigy	Verfahren zur Herstellung von 1,3,4-Thiadiazolen
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
FR2104932A1 (en) *	1970-09-08	1972-04-28	Ferlux	O-hydroxyphenyl pyrazoles - hypocholesterolemics anti inflammatories analgesics etc
US3907824A (en) *	1973-06-18	1975-09-23	American Cyanamid Co	Preparation of 1-alkyl-3,5-diphenylpyrazoles and 1,2-dialkyl-3,5-diphenylpyrazolium salts
ZA744908B (en) *	1973-09-17	1975-08-27	American Cyanamid Co	Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en)	1980-11-10	1985-05-02	Gersonde Klaus	Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja)	1982-01-06	1983-07-13	Nec Corp	デ−タ処理装置
DE3374837D1 (en)	1982-02-17	1988-01-21	Ciba Geigy Ag	Lipids in the aqueous phase
DE3218121A1 (de)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Arzneimittel zur tumorbehandlung
EP0102324A3 (de)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipide und Tenside in wässriger Phase
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE159858T1 (de)	1983-09-26	1997-11-15	Ehrenfeld Udo	Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
PH27357A (en) *	1989-09-22	1993-06-21	Fujisawa Pharmaceutical Co	Pyrazole derivatives and pharmaceutical compositions comprising the same
JPH04124178A (ja) *	1990-09-12	1992-04-24	Sds Biotech Kk	複素環式化合物および該化合物を含有する除草剤
DE4126543A1 (de)	1991-08-10	1993-02-11	Chem & Pharm Patent Hold Ltd	3(5)-(hydroxyaryl)-pyrazole und ihre verwendung als wirkstoffe in arzneimittel
DE19643037A1 (de)	1996-10-18	1998-04-23	Boehringer Ingelheim Kg	Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
YU86801A (sh) *	1999-06-10	2004-07-15	Warner-Lambert Company	Izoindol derivati korisni u inhibiciji agregacije amiloidnih proteina i snimanju amiloidnih naslaga
US20010049373A1 (en)	2000-01-28	2001-12-06	Chalquest Richard R.	Materials and methods for killing nematodes and nematode eggs
DK1334091T3 (da) *	2000-08-24	2012-10-15	Univ Pittsburgh	Thioflavinderivater og deres anvendelse til diagnose og terapi af Alzheimer's sygdom
US7119120B2 (en) *	2001-12-26	2006-10-10	Genzyme Corporation	Phosphate transport inhibitors
AU2003249597B2 (en) *	2002-03-08	2007-06-28	Merck Sharp & Dohme Corp.	Mitotic kinesin inhibitors
DE60328182D1 (de) *	2002-05-01	2009-08-13	Merck Sharp & Dohme	Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
WO2003101927A1 (en) *	2002-05-31	2003-12-11	Proteotech, Inc.	Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
US20070276034A1 (en)	2002-05-31	2007-11-29	Luke Esposito	Compounds, compositions and methods for the treatment of synucleinopathies
US8829198B2 (en) *	2007-10-31	2014-09-09	Proteotech Inc	Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
TW200413009A (en) *	2002-10-04	2004-08-01	Univ Pennsylvania	Biphenyls and fluorenes as imaging agents in alzheimer's disease
WO2004033432A1 (ja) *	2002-10-09	2004-04-22	Ssp Co., Ltd.	抗真菌活性を有する新規ピラゾール化合物
GB0225474D0 (en) *	2002-11-01	2002-12-11	Merck Sharp & Dohme	Therapeutic agents
GB0303503D0 (en)	2003-02-14	2003-03-19	Novartis Ag	Organic compounds
US20050113423A1 (en) *	2003-03-12	2005-05-26	Vangoor Frederick F.	Modulators of ATP-binding cassette transporters
ES2887054T3 (es) *	2003-04-11	2021-12-21	Ptc Therapeutics Inc	Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
US7220745B2 (en)	2003-05-15	2007-05-22	Rigel Pharmaceuticals	Heterocyclic compounds useful to treat HCV
CA2560314A1 (en) *	2004-03-29	2005-10-20	Merck & Co., Inc.	Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
AU2005245411B2 (en) *	2004-05-14	2009-04-23	Irm Llc	Compounds and compositions as PPAR modulators
GB0502277D0 (en) *	2005-02-04	2005-03-09	Amersham Plc	Novel imaging agents
BRPI0606902A2 (pt) *	2005-02-14	2009-07-28	Wyeth Corp	composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
TW200720254A (en) *	2005-04-07	2007-06-01	Nippon Kayaku Kk	Use of 3,5-diphenyl pyrazole derivatives as anti-tumor agent
AU2006201739A1 (en) *	2005-05-05	2006-11-23	The University Of North Carolina At Chapel Hill	Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles
US20070031328A1 (en)	2005-06-24	2007-02-08	Kung Hank F	Radiolabeled-pegylation of ligands for use as imaging agents
US20070197532A1 (en) *	2005-11-18	2007-08-23	Cao Sheldon X	Glucokinase activators
EP1956013B1 (en) *	2005-11-30	2016-04-13	Fujifilm RI Pharma Co., Ltd.	Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
MX2008012738A (es) *	2006-04-03	2009-02-06	Astellas Pharma Inc	Heterocompuesto.
US20080015193A1 (en) *	2006-06-20	2008-01-17	Mendoza Jose S	Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
WO2008131148A1 (en) *	2007-04-19	2008-10-30	The Trustees Of The University Of Pennsylvania	Diphenyl-heteroaryl derivatives and their use for binding and imaging amyloid plaques
JP2009203166A (ja) *	2008-02-26	2009-09-10	Nagasaki Univ	ジフェニルオキサジアゾール誘導体含有診断用組成物
HUE025984T2 (hu) *	2008-05-14	2016-05-30	Scripps Research Inst	Szfingozin foszfát receptor új modulátorai
AU2009253046A1 (en) *	2008-05-30	2009-12-03	Foster Wheeler Energia Oy	Method of and system for generating power by oxyfuel combustion

2009
- 2009-06-09 WO PCT/EP2009/004144 patent/WO2010000372A2/en not_active Ceased
- 2009-06-09 AU AU2009266098A patent/AU2009266098B2/en active Active
- 2009-06-09 HU HUE13176579A patent/HUE043090T2/hu unknown
- 2009-06-09 ES ES09772072T patent/ES2862923T3/es active Active
- 2009-06-09 US US12/996,833 patent/US20110293520A1/en not_active Abandoned
- 2009-06-09 EP EP09772072.6A patent/EP2307381B1/en active Active
- 2009-06-09 RU RU2010154272/04A patent/RU2531915C2/ru active
- 2009-06-09 KR KR1020117000508A patent/KR101787112B1/ko active Active
- 2009-06-09 PT PT13176579T patent/PT2684873T/pt unknown
- 2009-06-09 PL PL13176579T patent/PL2684873T3/pl unknown
- 2009-06-09 PL PL09772072T patent/PL2307381T3/pl unknown
- 2009-06-09 CA CA2726999A patent/CA2726999C/en active Active
- 2009-06-09 ES ES13176579T patent/ES2714453T3/es active Active
- 2009-06-09 DK DK09772072.6T patent/DK2307381T3/da active
- 2009-06-09 TR TR2019/04041T patent/TR201904041T4/tr unknown
- 2009-06-09 CN CN200980121681.4A patent/CN102056903B/zh active Active
- 2009-06-09 NZ NZ588442A patent/NZ588442A/xx unknown
- 2009-06-09 EP EP13176579.4A patent/EP2684873B1/en active Active
- 2009-06-09 HU HUE09772072A patent/HUE053352T2/hu unknown
- 2009-06-09 JP JP2011512038A patent/JP5896739B2/ja active Active
- 2009-06-09 MX MX2010012655A patent/MX339144B/es active IP Right Grant
- 2009-06-09 EP EP13176577.8A patent/EP2687513B1/en active Active
- 2009-06-09 BR BRPI0913609A patent/BRPI0913609B8/pt active IP Right Grant
- 2009-06-09 BR BR122019022071A patent/BR122019022071B8/pt active IP Right Grant
- 2009-06-09 PT PT97720726T patent/PT2307381T/pt unknown
- 2009-06-09 DK DK13176579.4T patent/DK2684873T3/en active
2010
- 2010-10-03 IL IL208377A patent/IL208377A/en active IP Right Grant
- 2010-12-07 CL CL2010001369A patent/CL2010001369A1/es unknown
- 2010-12-08 ZA ZA2010/08820A patent/ZA201008820B/en unknown
2014
- 2014-02-03 CL CL2014000270A patent/CL2014000270A1/es unknown
2015
- 2015-12-16 JP JP2015245186A patent/JP6307060B2/ja active Active
- 2015-12-16 JP JP2015245187A patent/JP6276744B2/ja active Active
- 2015-12-22 US US14/978,964 patent/US10071966B2/en active Active
2018
- 2018-08-03 US US16/054,416 patent/US10435373B2/en active Active

Also Published As

Publication number	Publication date
HUE043090T2 (hu)	2019-08-28
HUE053352T2 (hu)	2021-06-28
US20160185730A1 (en)	2016-06-30
EP2684873A1 (en)	2014-01-15
AU2009266098A1 (en)	2010-01-07
PL2307381T3 (pl)	2021-07-05
CN102056903B (zh)	2015-04-15
WO2010000372A2 (en)	2010-01-07
PT2684873T (pt)	2019-04-26
BRPI0913609A2 (pt)	2015-11-24
BRPI0913609B8 (pt)	2021-05-25
JP6276744B2 (ja)	2018-02-07
WO2010000372A3 (en)	2010-05-27
CN102056903A (zh)	2011-05-11
US10435373B2 (en)	2019-10-08
KR101787112B1 (ko)	2017-11-15
US20180346426A1 (en)	2018-12-06
AU2009266098B2 (en)	2015-01-22
US10071966B2 (en)	2018-09-11
BR122019022071B8 (pt)	2021-07-27
TR201904041T4 (tr)	2019-04-22
ES2862923T3 (es)	2021-10-08
KR20110022666A (ko)	2011-03-07
EP2687513A1 (en)	2014-01-22
RU2010154272A (ru)	2012-07-20
ZA201008820B (en)	2011-12-28
DK2307381T3 (da)	2021-03-15
NZ588442A (en)	2013-01-25
JP2011522810A (ja)	2011-08-04
JP2016102126A (ja)	2016-06-02
JP6307060B2 (ja)	2018-04-04
ES2714453T3 (es)	2019-05-28
MX2010012655A (es)	2010-12-21
EP2687513B1 (en)	2020-12-02
US20110293520A1 (en)	2011-12-01
EP2307381B1 (en)	2021-01-13
CA2726999C (en)	2017-05-02
EP2684873B1 (en)	2019-01-16
RU2531915C2 (ru)	2014-10-27
IL208377A (en)	2017-11-30
DK2684873T3 (en)	2019-04-01
BRPI0913609B1 (pt)	2020-02-18
JP2016121136A (ja)	2016-07-07
CL2010001369A1 (es)	2011-06-17
IL208377A0 (en)	2010-12-30
EP2307381A2 (en)	2011-04-13
JP5896739B2 (ja)	2016-03-30
PL2684873T3 (pl)	2019-07-31
BR122019022071B1 (pt)	2020-12-29
CA2726999A1 (en)	2010-01-07
MX339144B (es)	2016-05-13
PT2307381T (pt)	2021-03-15

Publication	Publication Date	Title
CY1124874T1 (el)	2022-11-25	Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου
EA201170227A1 (ru)	2011-06-30	Имидазолкарбоксамиды
EA200970580A1 (ru)	2009-12-30	Таннат разагилина
CL2007001040A1 (es)	2008-03-14	Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
WO2009156462A3 (en)	2010-05-27	Organic compounds
CL2016003015A1 (es)	2017-06-30	Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)(divisional de sol. n°230-11).
CY1117615T1 (el)	2017-04-26	Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
EA201000395A1 (ru)	2010-08-30	Фунгицидные производные 2-алкилтио-2-хинолинилоксиацетамида
DK3309139T3 (da)	2023-12-18	Process for the preparation of 2,3,3,3-trifluoropropene
UA107791C2 (en)	2015-02-25	Pesticidal compositions
WO2008013838A3 (en)	2008-07-31	Pyridizinone derivatives
CL2007002949A1 (es)	2008-05-30	Forma cristalina del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida; proceso para la preparacion de dicha forma cristalina; composicion fitoprotectora;
SMP200900085B (it)	2010-11-12	3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0918472A2 (pt)	2015-12-01	composto 2,4-diaminopirimidina
MA32797B1 (fr)	2011-11-01	Formes cristallines de la (r)-5[3-chloro-4-(2,3-dihydroxy-propoxy)-benz-[z]-ylidène]-2-([z]-propylimino)-3-o-tolyl- thiazolidin-4-one
EA201000814A1 (ru)	2010-12-30	5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
EA201000329A1 (ru)	2010-08-30	Циклические депсипептиды
BRPI0919918A2 (pt)	2015-08-18	Composto de vanilina e de etilvanilina, processo de preparação do mesmo, composição, e, aplicação do composto.
UA106880C2 (uk)	2014-10-27	Нові гербіциди
CL2007001838A1 (es)	2008-02-08	Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
CL2008000629A1 (es)	2008-08-29	Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
CL2007003875A1 (es)	2008-04-18	Compuestos derivados de amidas del acido 3-amino tetrahidrofurano-3-carboxilico; procedimiento de preparacion de dichos compuestos.
WO2012075015A3 (en)	2012-08-23	Oral metronidazole pharmaceutical compositions
MA33915B1 (fr)	2013-01-02	Nouveaux derives d' (heterocycle-piperidine condensee)-(piperazinyl)-1-alcanone ou d' (heterocycle-pyrrolidine condensee)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
BRPI0811557A2 (pt)	2019-09-24	composto, composição farmacêutica, método de tratamento ou profilaxia de uma condição inflamatória.